New report reveals need for pricing and reimbursement and procurement reforms to ensure patient access and healthcare sustainability

New report assesses progress on biosimilar medicine policies… 29 March 2021 Biosimilar medicines are increasingly relevant to public health as emphasised by the…
Protecting health: Active generic and biosimilar policies… 3 March 2020 Equitable and sustainable access to medicines is a concern across…
Factsheet: Market and regulatory reforms to ensure… 21 May 2021 Open
EU manufacturers call for urgent reforms to achieve… 30 September 2019 Brussels, 30 September 2019 – Amidst discussions on the International…